Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.51 |
| ▸ | AR | P10275 | 5/20 | 0.48 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25691424 | 0.93 | CRBN (0.45) | CRBNDDB1ARPLK4CDK9 | |
| SCHEMBL31306505 | 0.88 | CRBN (0.53) | CRBNDDB1ARPLK4CDK9 | |
| SCHEMBL23134596 | 0.88 | CRBN (0.58) | CRBNDDB1ARPLK4CDK9 | |
| SCHEMBL29822222 | 0.87 | CRBN (0.54) | CRBNDDB1ESR1 | |
| SCHEMBL23117892 | 0.87 | CRBN (0.54) | CRBNDDB1ESR1 | |
| SCHEMBL23117896 | 0.87 | CRBN (0.54) | CRBNDDB1ESR1 | |
| SCHEMBL31306538 | 0.86 | CRBN (0.58) | CRBNDDB1ARPLK4CDK9 | |
| SCHEMBL28795318 | 0.85 | CDK9 (0.51) | CRBNDDB1ARPLK4CDK9 | |
| SCHEMBL28795171 | 0.85 | CDK9 (0.51) | CRBNDDB1ARPLK4CDK9 | |
| SCHEMBL31458460 | 0.85 | CDK9 (0.51) | CRBNDDB1ARPLK4CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885DDB1 1112/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.